Fox Run Management L.L.C. Purchases New Shares in Boston Scientific Corporation $BSX

Fox Run Management L.L.C. acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,606 shares of the medical equipment provider’s stock, valued at approximately $2,207,000. Boston Scientific comprises about 0.3% of Fox Run Management L.L.C.’s portfolio, making the stock its 16th biggest position.

Other institutional investors also recently modified their holdings of the company. Gerber Kawasaki Wealth & Investment Management lifted its holdings in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 99 shares in the last quarter. Crown Wealth Group LLC grew its position in shares of Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after buying an additional 100 shares during the period. Sound View Wealth Advisors Group LLC increased its position in shares of Boston Scientific by 3.9% in the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 103 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares in the last quarter. Finally, Scotia Capital Inc. boosted its holdings in shares of Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after buying an additional 104 shares during the period. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Mizuho dropped their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Needham & Company LLC cut their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Barclays decreased their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Wells Fargo & Company lowered their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Stock Up 1.2%

Shares of NYSE:BSX opened at $75.27 on Wednesday. The company has a market capitalization of $111.70 billion, a price-to-earnings ratio of 38.80, a P/E/G ratio of 1.03 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50. The business’s 50-day moving average is $88.52 and its 200-day moving average is $96.13. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.